

# Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A64384BA3481EN.html>

Date: May 2024

Pages: 129

Price: US\$ 6,499.00 (Single User License)

ID: A64384BA3481EN

## Abstracts

The 7 major ataxia markets reached a value of US\$ 23.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 43.1 Billion by 2034, exhibiting a growth rate (CAGR) of 5.49% during 2024-2034.

The ataxia market has been comprehensively analyzed in IMARC's new report titled "Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ataxia is a medical condition in which there's a loss of muscle coordination during voluntary movements. It is a neurological disorder that affects the ability to control and coordinate muscular motions, leading to difficulties with balance, walking, speaking, and performing fine motor skills. The common indications of this disease include an unsteady gait, clumsiness, fatigue, slurred speech, trembling or shaking of the hands, trouble with eye movements, etc. These symptoms can range in severity from moderate to severe, and they can worsen over time. The diagnosis of ataxia involves a combination of clinical evaluation, medical history review, and neurological examination. The healthcare provider may perform blood workups to check for genetic markers, assess vitamin levels (mainly vitamin E and B12), detect liver and kidney function, and determine specific antibodies associated with the autoimmune causes of the disease. Several other diagnostic procedures, such as magnetic resonance imaging (MRI), computed tomography (CT) scans of the brain, lumbar puncture, etc., are utilized to examine the structure and evaluate any abnormalities or lesions among patients.

The increasing cases of various associated risk factors, including trauma, strokes, tumors, infections, etc., that can lead to damage or dysfunction in the central nervous system are primarily driving the ataxia market. In addition to this, the rising incidence of inherited conditions, resulting from genetic mutations that change the development or

function of the brain is also creating a positive outlook for the market. Moreover, the widespread adoption of effective therapeutic agents, like acetazolamide and 4-aminopyridine, to improve disease symptoms by affecting ion channels and neurotransmitter release in the cerebellum is further bolstering the market growth. Apart from this, the escalating application of physical and occupational therapies, since they target specific muscle groups to boost strength and flexibility, thereby promoting independence and quality of life in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of orthotic devices, such as ankle-foot orthoses (AFOs), owing to their several associated benefits, including corrected alignment and posture, enhanced stability, reduced risk of falls, etc., is expected to drive the ataxia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the ataxia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for ataxia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ataxia market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

## Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the ataxia market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the ataxia market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ataxia marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the ataxia market performed so far and how will it perform in the coming years?

What are the market shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the ataxia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the ataxia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of ataxia across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of ataxia by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of ataxia by gender across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of ataxia by type across the seven major markets?

How many patients are diagnosed (?2018-2034?) with ataxia across the seven major markets?

What is the size of the ataxia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of ataxia?

What will be the growth rate of patients across the seven major markets?

## Ataxia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for ataxia drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ataxia market?

What are the key regulatory events related to the ataxia market?

What is the structure of clinical trial landscape by status related to the ataxia market?  
What is the structure of clinical trial landscape by phase related to the ataxia market?  
What is the structure of clinical trial landscape by route of administration related to the ataxia market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 ATAXIA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 ATAXIA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 ATAXIA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (?2018-2034?)
  - 7.2.4 Epidemiology by Gender (?2018-2034?)
  - 7.2.5 Epidemiology by Type (?2018-2034?)
  - 7.2.6 Diagnosed Cases (?2018-2034?)
  - 7.2.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (?2018-2034?)
  - 7.3.4 Epidemiology by Gender (?2018-2034?)
  - 7.3.5 Epidemiology by Type (?2018-2034?)
  - 7.3.6 Diagnosed Cases (?2018-2034?)
  - 7.3.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (?2018-2034?)
  - 7.4.4 Epidemiology by Gender (?2018-2034?)
  - 7.4.5 Epidemiology by Type (?2018-2034?)
  - 7.4.6 Diagnosed Cases (?2018-2034?)
  - 7.4.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (?2018-2034?)
  - 7.5.4 Epidemiology by Gender (?2018-2034?)
  - 7.5.5 Epidemiology by Type (?2018-2034?)
  - 7.5.6 Diagnosed Cases (?2018-2034?)
  - 7.5.7 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (?2018-2034?)
  - 7.6.4 Epidemiology by Gender (?2018-2034?)
  - 7.6.5 Epidemiology by Type (?2018-2034?)
  - 7.6.6 Diagnosed Cases (?2018-2034?)

7.6.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (?2018-2034?)

7.7.4 Epidemiology by Gender (?2018-2034?)

7.7.5 Epidemiology by Type (?2018-2034?)

7.7.6 Diagnosed Cases (?2018-2034?)

7.7.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (?2018-2034?)

7.8.4 Epidemiology by Gender (?2018-2034?)

7.8.5 Epidemiology by Type (?2018-2034?)

7.8.6 Diagnosed Cases (?2018-2034?)

7.8.7 Patient Pool/Treated Cases (?2018-2034?)

## 7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (?2018-2034?)

7.9.4 Epidemiology by Gender (?2018-2034?)

7.9.5 Epidemiology by Type (?2018-2034?)

7.9.6 Diagnosed Cases (?2018-2034?)

7.9.7 Patient Pool/Treated Cases (?2018-2034?)

## **8 ATAXIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

## **9 ATAXIA - UNMET NEEDS**

## **10 ATAXIA - KEY ENDPOINTS OF TREATMENT**

## **11 ATAXIA - MARKETED PRODUCTS**

11.1 List of Ataxia Marketed Drugs Across the Top 7 Markets

11.1.1 Skyclarys (Omaveloxolone) - Reata Pharmaceuticals



- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 ATAXIA - PIPELINE DRUGS**

### 12.1 List of Ataxia Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 Vatiquinone - PTC Therapeutics

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 RT 001 - Retrotope

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 SLS005 - Seelos Therapeutics

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

#### 12.1.4 MIN 102 - Minoryx Therapeutics

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

#### 12.1.5 DT216 - Design Therapeutics

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. ATAXIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. ATAXIA – CLINICAL TRIAL LANDSCAPE**

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

### **15 ATAXIA - MARKET SCENARIO**

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Ataxia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Ataxia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Ataxia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Ataxia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Ataxia - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Ataxia - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Ataxia - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

15.4.2.2 Market Forecast by Therapies (2024-2034)

- 15.4.3 Ataxia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Ataxia - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Ataxia - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Ataxia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Ataxia - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Ataxia - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Ataxia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Ataxia - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Ataxia - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Ataxia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Ataxia - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Ataxia - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Ataxia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Ataxia - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Ataxia - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)  
15.9.3 Ataxia - Access and Reimbursement Overview

## **16 ATAXIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ATAXIA MARKET - SWOT ANALYSIS**

17.1 Strengths  
17.2 Weaknesses  
17.3 Opportunities  
17.4 Threats

## **18 ATAXIA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Ataxia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A64384BA3481EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A64384BA3481EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

